Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Dicerna Pharmaceuticals Inc banner
D

Dicerna Pharmaceuticals Inc
F:DPL

Watchlist Manager
Dicerna Pharmaceuticals Inc
F:DPL
Watchlist
Price: 33.51 EUR
Market Cap: €2.6B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

DPL Price Targets Summary
Dicerna Pharmaceuticals Inc

There are no price targets for DPL.
DPL Lowest Forecast
Wall Street Target
Not Available
DPL Average Forecast
Wall Street Target
Not Available
DPL Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Dicerna Pharmaceuticals Inc Competitors:
Price Targets
PAYS
Paysign Inc
181% Upside
MTRX
Matrix Service Co
52% Upside
WOOF
Petco Health and Wellness Company Inc
42% Upside
IDXX
IDEXX Laboratories Inc
23% Upside
PAYS
Paysign Inc
181% Upside
MTRX
Matrix Service Co
52% Upside
WOOF
Petco Health and Wellness Company Inc
42% Upside
IDXX
IDEXX Laboratories Inc
23% Upside
VRNS
Varonis Systems Inc
101% Upside

Revenue
Forecast

48% / Year
Past Growth
8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
48% / Year
Past Growth
8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 8 years the compound annual growth rate for Dicerna Pharmaceuticals Inc's revenue is 48%. The projected CAGR for the next 2 years is 8%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Dicerna Pharmaceuticals Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

See Also

Summary
DPL intrinsic value, competitors valuation, and company profile.
DCF Valuation
DPL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DPL stock valuation using valuation multiples.
Wall Street Estimates
DPL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DPL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DPL's stock price target?
Not Available

DPL doesn't have any price targets made by Wall Street professionals.

What is Dicerna Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Dicerna Pharmaceuticals Inc's revenue is 48%. The projected CAGR for the next 2 years is 8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.